Celcuity Inc. has released a presentation highlighting the potential of treating cancers that involve the PI3K/AKT/mTOR pathway. The presentation underscores the significant untapped potential in effectively treating these cancers with gedatolisib, a PAM pathway inhibitor noted for its differentiated mechanism of action and pharmacokinetic profile. Promising data has been shown in first-line and second-line patients with HR+/HER2- advanced breast cancer, with a Phase 3 study currently enrolling second-line patients and another study expected to begin soon for first-line patients. The presentation also suggests a strong scientific rationale for developing gedatolisib for prostate cancer indications, citing interdependencies between the PAM pathway and hormonal pathways. Celcuity is well-positioned to advance multiple potential blockbuster indications in breast and prostate cancer, leveraging its cash reserves to fund operations through 2026. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.